ABOUT THIS EVENT

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, visited the Nasdaq MarketSite in Times Square.

In honor of the occassion, Akero President and CEO Andrew Cheng, M.D., Ph.D., rang the Closing Bell.